Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialEurope PMCOpen access

Downregulation of CPPED1 expression improves glucose metabolism in vitro in adipocytes

Vaittinen M., Kaminska D., Käkelä P., Eskelinen M., Kolehmainen M., Pihlajamäki J.

Randomized Controlled Trial, published in Diabetes (2013) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Diabetes (2013)
Reported sample size
—
Source database
Europe PMC
PMID
23939394
PMCID
PMC3806586
DOI
10.2337/db13-0830
Citations
20

Abstract (original English)

We have previously demonstrated that the expression of calcineurin-like phosphoesterase domain containing 1 (CPPED1) decreases in adipose tissue (AT) after weight reduction. However, the function of CPPED1 in AT is unknown. Therefore, we investigated whether the change in CPPED1 expression is connected to changes in adipocyte glucose metabolism. First, we confirmed that the expression of CPPED1 decreased after weight loss in subcutaneous AT. Second, the expression of CPPED1 did not change during adipocyte differentiation. Third, CPPED1 knockdown with small interfering RNA increased expression of genes involved in glucose metabolism (adiponectin, adiponectin receptor 1, and GLUT4) and improved insulin-stimulated glucose uptake. To conclude, CPPED1 is a novel molecule involved in AT biology, and CPPED1 is involved in glucose uptake in adipocytes.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipose TissueCells, CulturedAdipocytesHumansWeight LossInsulinCalcineurinGlucoseRNA, Small InterferingCell Differentiation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.